Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.
Read the analysis →Decision-useful coverage for executives, investors, regulators and scientists.
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The…
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-07 Achieve’s Cytisinicline CRL: The Rejection That Was Priced Before It Arrived Same…
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-06 The CMC Execution Crisis: Why Unicycive’s Second CRL Is a Warning Shot…
Witfire Elite · Licensing Risk Brief · CNS AlzeCure’s $2.2 Billion NeuroRestore Deal Is a Risk Transfer, Not a Victory AlzeCure did not prove…
Original analysis connecting scientific evidence, regulatory decisions and market value.
Witfire Elite · Launch Execution · Competitive Strategy Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell. Viridian entered a $1.9 billion…
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-05 FDA Issues CRL to Sobi for NASP: The Agency Rejected the Control…
Witfire Elite · Competitive Strategy · Japan Pharma Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study.…
Witfire Elite Review, July 2026 -The Weakest Layer: The Stabilizer Ceiling, Eplontersen's CARDIO-TTRansform Miss, Unicycive OLC CRL.
Read the digital issue →
